Dr. Rigolli is a Cardiologist and Physician-Scientist (MD, DPhil), currently serving as Executive Director, Cardio-Renal, in Clinical Development at Eli Lilly and Company. Her expertise spans cardiomyopathies, imaging, heart failure, and cardio-renal.
Trained at the University of Oxford, where she was awarded a DPhil, and at the University of Verona, Italy, her academic research examined imaging-based clinical outcomes and novel therapeutic targets in heart failure, aortic stenosis, and cardiomyopathies. At UC San Diego, she worked on rare cardiomyopathies and gene replacement therapy approaches.
In her biopharmaceutical career, she has led clinical trials across the cardiovascular portfolio, with focus on cardiac myosin inhibition in HFpEF and cardiomyopathies at MyoKardia and Bristol Myers Squibb. At Lilly, she advances innovative cardiovascular-renal therapies for patients with cardiometabolic disease.
Right ventricular dysfunction is associated with late mortality in severe aortic stenosis: results from a multi-centre outcome study in patients undergoing aortic valve replacement
Event: ESC Congress 2019
Topic: Epidemiology, Prognosis, Outcome
Session: Imaging parameters in valvular heart disease
